Introduction
Methods
Eligibility criteria
Literature search
Study selection
Data collection process and data items
Risk of bias in individual studies
Efficacy measures
Patient-reported home diaries which give the following outcomes
Modified abnormal involuntary movement scale (mAIMS)
UPDRS part 3 and part 4 (items 32 and 33)
Lang-Fahn activities of daily living dyskinesia scale (LFADLDS)
Synthesis of results
Calculation of missing data
Risk of bias across studies
Results
Study selection
Study characteristics
Study ID | Design | Final endpoint | Group | N | Age* | Male | mAIMS* | UPDRS-III* | UPDRS-IV (items 32 and 33)* |
---|---|---|---|---|---|---|---|---|---|
Berg 2010 (Study 1) | RCT | 2 weeks | Mavoglurant | 15 | 60.7 (10.5) | 60% | 11.4 (4.79) | 26.6 (14.78) | 4.7 (1.03) |
Placebo | 16 | 61.4 (10.2) | 43.8% | 9.1 (3.87) | 22.1 (9.77) | 4.1 (0.89) | |||
Berg 2010 (Study 2) | RCT | 3 weeks | Mavoglurant | 14 | 65.6 (7.5) | 64.3% | 16 (4.07) | 26.1 (16.67) | 5.4 (0.95) |
Placebo | 14 | 66.1 (6.5) | 57.1% | 16.3 (4.32) | 26 (9.68) | 4.8 (0.89) | |||
Stocchi 2013 | RCT | 13 weeks | Mavoglurant 20 mg | 22 | 66.2 (8.16) | 45.5% | 14.5 (4.64) | 16.6 (8.13) | 5.1 (0.89) |
Mavoglurant 50 mg | 22 | 66.4 (7.96) | 59.1% | 12.9 (5.03) | 18.6 (7.97) | 4.9 (0.01) | |||
Mavoglurant 100 mg | 23 | 65.6 (9.47) | 60.9% | 13.3 (5.25) | 18.5 (9.65) | 4.8 (0.8) | |||
Mavoglurant 150 mg | 22 | 66 (10.54) | 63.6% | 13.9 (5.08) | 18.9 (9.25) | 4.8 (0.73) | |||
Mavoglurant 200 mg | 44 | 63.4 (8.98) | 54.5% | 13.4 (4.91) | 17.5 (9.31) | 5 (0.88) | |||
Placebo | 64 | 64.8 (8.17) | 46.9% | 13.5 (4.68) | 16.9 (9.39) | 4.9 (0.82) | |||
Kumar 2016 | RCT | 5 weeks | Mavoglurant | 7 | 61.3 (8.98) | 57.1% | NR | 22.3 (15.32) | NR |
Placebo | 7 | 61.4 (6) | 71.4% | NR | 16.1 (7.8) | NR | |||
Trenkwalder 2016 (study 1) | RCT | 12 weeks | Mavoglurant 100 mg | 36 | 65.9 (6.97) | 52.8% | 12.5 (4.88) | 20.5 (10.13) | 4.8 (0.87) |
Placebo | 25 | 66.6 (7.04) | 60.0% | 12.8 (5.08) | 19.5 (7.91) | 4.8 (0.66) | |||
Trenkwalder 2016 (study 2) | RCT | 12 weeks | Mavoglurant 150 mg | 39 | 64.4 (8.68) | 56.4% | 12.38 (4.178) | 18.05 (9.409) | 4.67 (0.898) |
Mavoglurant 200 mg | 78 | 64.4 (8.84) | 52.6% | 12.59 (5.062) | 20.26 (11.319) | 4.82 (0.833) | |||
Placebo | 37 | 64.2 (9.02) | 56.8% | 11.73 (5.064) | 19.32 (9.548) | 4.81 (0.811) |
Drug efficacy
Off-time
Total on time
On time without dyskinesia
On time with troublesome dyskinesia
mAIMS
Lang-Fahn activities of daily living dyskinesia scale (LFADLDS)
UPDRS-IV (items 32 and 33)
UPDRS-III
Adverse events
Adverse event | N of RCTs | N patients | RR [95% CI] |
---|---|---|---|
Dizziness | 5 | 471 | 4.19 [1.83 to 9.64] |
Dyskinesia | 6 | 585 | 0.74 [0.46 to 1.17] |
Euphoria | 3 | 73 | 3.70 [0.64 to 21.29] |
Fatigue | 5 | 471 | 2.11 [0.72 to 6.15] |
Insomnia | 4 | 426 | 1.90 [0.58 to 6.23] |
Hallucination | 2 | 211 | 4.55 [0.86 to 24.04] |
Nausea | 4 | 274 | 2.02 [0.48 to 8.46] |